Literature DB >> 30240004

In vivo microscopic and optical coherence tomography classification of neurotrophic keratopathy.

Leonardo Mastropasqua1, Mario Nubile1, Manuela Lanzini1, Roberta Calienno1, Harminder S Dua2.   

Abstract

Neurotrophic keratopathy (NK) is a rare degenerative corneal disorder characterized by instability of epithelial integrity with consequent epithelial defects that can worsen up to persistent epithelial defects with stromal melting and ulceration. The pathogenesis of NK springs from a variable degree of damage to the trigeminal nerve plexus, leading to a reduction or total loss of corneal sensitivity. Mackie classification (1995) distinguishes three stages of NK, based on the severity of clinical presentation. The technological innovations in corneal diagnostic imaging allow clinicians to accurately study the morphometry and morphology of corneal structure with microscopic resolution. In this study, 45 patients affected by NK at different stages underwent in vivo confocal microscopy (IVCM) and anterior segment optical coherence tomography (AS-OCT) with particular attention to analyze subbasal nerve plexus fibers and the stromal structure. At the light of IVCM and AS-OCT observations, we propose a different staging of NK with respect to the Mackie's classification that takes into account the severity of subbasal nerve fibers damage and the extension in depth of stromal ulceration; this classification better defines, at the time of diagnosis, the cellular and structural alterations in the affected corneas, with possible prognostic and therapeutic values in the management of NK.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  anterior segment optical coherence tomography (AS-OCT); corneal nerves; in vivo confocal microscopy (IVCM); neurotrophic keratopathy (NK)

Mesh:

Year:  2018        PMID: 30240004     DOI: 10.1002/jcp.27345

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Dorsolateral medullary infarction registry: a study protocol for a prospective, multicentric registry.

Authors:  Jing Wang; Pei Liu; Zhongzhong Liu; Ye Tian; Guilian Zhang; Jun Guo; Li Li; Zhiqin Liu; Zucheng Han; Wenjuan Lin; Xuemei Lin; Qingli Lu; Yan Liu; Qiaoqiao Chang; Songdi Wu
Journal:  BMC Neurol       Date:  2021-01-12       Impact factor: 2.474

2.  Recombinant Human Nerve Growth Factor (Cenegermin)-Driven Corneal Wound Healing Process: An Evidence-Based Analysis.

Authors:  Chiara Bonzano; Sara Olivari; Carlo Alberto Cutolo; Angelo Macrì; Daniele Sindaco; Davide Borroni; Elisabetta Bonzano; Carlo Enrico Traverso
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

3.  Tear proteomics reveals the molecular basis of the efficacy of human recombinant nerve growth factor treatment for Neurotrophic Keratopathy.

Authors:  Damiana Pieragostino; Manuela Lanzini; Ilaria Cicalini; Maria Concetta Cufaro; Verena Damiani; Leonardo Mastropasqua; Vincenzo De Laurenzi; Mario Nubile; Paola Lanuti; Giuseppina Bologna; Luca Agnifili; Piero Del Boccio
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

4.  Role of the Neurokinin-1 Receptor in the Promotion of Corneal Epithelial Wound Healing by the Peptides FGLM-NH2 and SSSR in Neurotrophic Keratopathy.

Authors:  Ryoji Yanai; Teruo Nishida; Makoto Hatano; Sho-Hei Uchi; Naoyuki Yamada; Kazuhiro Kimura
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-07-01       Impact factor: 4.799

5.  Genetically Encoded Calcium Indicators for In Situ Functional Studies of Corneal Nerves.

Authors:  Matthew T McPheeters; Brecken J Blackburn; William J Dupps; Andrew M Rollins; Michael W Jenkins
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

6.  The Role of Hi-Tech Devices in Assessment of Corneal Healing in Patients with Neurotrophic Keratopathy.

Authors:  Leandro Inferrera; Emanuela Aragona; Adam Wylęgała; Antonio Valastro; Gianluigi Latino; Elisa I Postorino; Romana Gargano; Bogusława Orzechowska-Wylęgała; Edward Wylęgała; Anna M Roszkowska
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.